About the Seminar:
Discovering Novel Driver Mutations from Tumor Samples Using the Arima Genomics Oncology Panel for Hi-C
Wednesday, March 1, 2023 | 2:00 pm – 3:00 pm ET
Join us to learn how 3D genomics is enabling tumor classification, identifying novel drivers of disease, and maximizing discovery. In this session, Kristin Sikkink, PhD, Director of Research at Arima Genomics, will cover a product overview and examples of how 3D genomics is reshaping how we understand disease, and producing exciting new opportunities in cancer research and beyond. She will be joined by Claudia Lalancette, PhD, Managing Director at Epigenomics Core, who will share data from Arima’s FFPE oncology Hi-C kit.
Register Now
Meet the Speakers:
Kristin Sikkink, PhD
Director of Research, Arima GenomicsKristin is our newly appointed Director of Research and holds a PhD in Biology. She leads and manages Arima's clinical and discovery research programs.
Claudia Lalancette, PhD
Managing Director, Epigenomics CoreClaudia brings more than 10 years of experience in genomics and microarrays to the Epigenomics Core. She obtained a Specialised Graduate Diploma (DESS) in Bioinformatics from Université du Québec à Montréal in 2014. Prior to joining the University of Michigan, Claudia worked at McGill University as a research associate screening compounds for toxicity potential, using high throughput techniques.